CRDL ▼ -12.2% - Cardiol Therapeutics Inc. $CRDL - Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission Cardiol Therapeutics shares fell 12.2% following the company's filing of a preliminary base shelf prospectus for up to US$150 million, accompanied by additional disclosure required after a review by the Ontario Securities Commission. The filing, which enables future capital raises, may have pressured the stock as investors digested the regulatory feedback and dilution implications from the authorized shelf offering. 10-SEP-2026 05:00 PM ET